ReviewInternational journal of molecular sciences2014
Battle against cancer: an everlasting saga of p53.
Review in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- RNA-binding protein ELAVL1 modulates WDR36 to inhibit p53 pathway and reduce calcium overload in retinal cells under acute pressure elevation.Open life sciences · 2026Article
- MDM2 as a therapeutic target in advanced biliary tract cancers.The oncologist · 2025Review
- A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma.Genome medicine · 2022Article
- Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer.Scientific reports · 2021Article
- CDC37L1 acts as a suppressor of migration and proliferation in gastric cancer by down-regulating CDK6.Journal of Cancer · 2021Article
- Review
- PUMA decreases the growth of prostate cancer PC-3 cells independent of p53.Oncology letters · 2017Article
- Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.International journal of molecular sciences · 2017Review
- Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.International journal of molecular sciences · 2016Review
- Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition.Oncotarget · 2016Article
- Article
- Tangeretin derivative, 5-acetyloxy-6,7,8,4'-tetramethoxyflavone induces G2/M arrest, apoptosis and autophagy in human non-small cell lung cancer cells in vitro and in vivo.Cancer biology & therapy · 2016Article
- Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance.Oncotarget · 2015Article
- Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis and autophagy in oral cancer SSC-4 cells.OncoTargets and therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the most life-threatening diseases characterized by uncontrolled growth and spread of malignant cells. The tumor suppressor p53 is the master regulator of tumor cell growth and proliferation. In response to various stress signals, p53 can be activated and transcriptionally induces a myriad of target genes, including both protein-encoding and non-coding genes, controlling cell cycle progression, DNA repair, senescence, apoptosis, autophagy and metabolism of tumor cells. However, around 50% of human cancers harbor mutant p53 and, in the majority of the remaining cancers, p53 is inactivated through multiple mechanisms. Herein, we review the recent progress in understanding the molecular basis of p53 signaling, particularly the newly identified ribosomal stress-p53 pathway, and the development of chemotherapeutics via activating wild-type p53 or restoring mutant p53 functions in cancer. A full understanding of p53 regulation will aid the development of effective cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.